GlaxoSmithKline Pharmaceuticals Ltd approves Q2 FY27 results, with consolidated revenue of ₹1,183.6 crore and net profit of ₹335.9 crore
- Revenue rose 20.8% year on year; operating margin was approximately 32.7%, excluding other income, with no exceptional item.
- Net profit increased 30.4% year on year; auditors issued unmodified limited-review conclusions.
- Appointed Sandeep Seth as Head – Ethics & Compliance; approved Walker Chandiok & Co LLP as statutory auditors for FY28–FY32, subject to shareholder approval.